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Abstract
Background: Liver transection is considered a critical factor influencing intra-operative blood loss. A
increase in the number of complex liver resections has determined a growing interest in new devices able
to ‘optimize’ the liver transection. The aim of this randomized controlled study was to compare a
radiofrequency vessel-sealing system with the ‘gold-standard’ clamp-crushing technique.
Methods: From January to December 2012, 100 consecutive patients undergoing a liver resection were
randomized to the radiofrequency vessel-sealing system (LF1212 group; N = 50) or to the clamp-crushing
technique (Kelly group, N = 50).
Results: Background characteristics of the two groups were similar. There were not significant differ-
ences between the two groups in terms of blood loss, transection time and transection speed. In spite of
a not-significant larger transection area in the LF1212 group compared with the Kelly group (51.5 versus
39 cm2, P = 0.116), the overall and ‘per cm2’ blood losses were similar whereas the transection speed was
better (even if not significantly) in the LF1212 group compared with the Kelly group (1.1 cm2/min versus
0.8, P = 0.089). Mortality, morbidity and bile leak rates were similar in both groups.
Conclusions: The radiofrequency vessel-sealing system allows a quick and safe liver transection similar
to the gold-standard clamp-crushing technique.
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Introduction
Excessive blood loss during a liver transection and the need for
blood transfusions have been shown to be correlated with higher
morbidity and mortality rates and with a worse long-term
outcome.1 Hepatic pedicle clamping and maintenance of a low
central venous pressure during a liver transection are commonly
used procedures in order to minimize the blood loss.2,3 The tech-
nique of a liver transection is considered another critical factor
influencing intra-operative blood loss. Randomized studies
comparing the clamp-crushing technique with other techniques
[Cavitron ultrasonic surgical aspirator (CUSA), the hydrojet dis-
sector and the radiofrequency dissecting sealer (RFDS)] have
shown that the clamp-crushing technique, usually associated with
hepatic pedicle clamping, resulted either in similar or lower blood
loss and transfusion requirements.4–6 Thereafter, the clamp-
crushing technique associated with bipolar humid coagulation is
generally considered to represent the reference standard against
which new methods must be compared.7
Over the years, there has been an increasing extension of the
indications for hepatic resection and in the use of pre-operative
chemotherapy. The progressive increase in the rate of com-
plex hepatic resections on a liver damaged by pre-operative
chemotherapy has determined a growing interest in new devices
able to shorten the transection time, to facilitate bloodless
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transections even without hepatic pedicle clamping and to reduce
bile leak.8
The LigasureTM Small Jaw Instrument (LF1212) (Covidien,
Boulder, CO, USA) is a vessel sealing system that can fuse vessels,
up to and including 7 mm, lymphatics and tissue bundles. The
LF1212 device has a Kelly shape that allows accurate liver crushing
in the standard fashion of the ‘classic’ clamp-crushing technique.
Moreover, some data seem to suggest that this type of vessel
sealing system may reduce the risk of bile leakage.9
The aim of this randomized controlled trial was to identify the
most safe and efficient device in terms of overall and ‘per cm2’
blood loss during a liver transection and in terms of transection
time and speed.
Materials and methods
At the Department of Surgical Oncology, Institute for Cancer
Research and Treament (IRCC) and at the Hepato-Biliary-
Pancreatic Surgery and Liver Transplantation Unit, University of
Modena and Reggio Emilia, Modena (Italy), from January to
December 2012, all patients considered for a curative liver resec-
tion were enrolled in this study, after giving written informed
consent. A total of 100 consecutive patients whose liver tumours
appeared resectable on intra-operative ultrasonography were ran-
domly assigned to undergo a liver transection using kellyclasia
plus humid bipolar coagulation (Kelly group: 50 patients) or the
Ligasuretm Small Jaw Instrument (Covidien) (LF1212 group: 50
patients) by the surgeon (Fig. 1). There were 62 men, and the
median (range) age was 64.7 (32.5–84.8) years.
Randomization took place in the operating room after a lapa-
rotomy, when the patients were deemed resectable. Patients not
eligible for a liver resection after a laparotomy were excluded from
the study. Patients were assigned to treatment at the ratio of 1:1
according to a computer-generated randomization list by means
of STATA software (version 10 ©; StataCorp LP, College Station,
TX, USA). Randomization was restricted by blocking with ran-
domly varying block size and stratified by centre.
Study design
The procedure was approved by the ethical committee of the
hospital.
Eligibility criteria included a liver resection either for benign or
malignant tumours, ‘good hepatic function’ defined as Child–
Pugh class A and a ICG Test ≤15%, an acceptable clotting profile
(platelet count 90 × 103), and adequate cardio-respiratory and
renal function. Patients requiring a bile duct resection, vascular
resection or undergoing emergency liver surgery were excluded
from the study.
Liver transection time and blood loss were calculated from the
beginning to the end of the liver resection. The amount of blood
loss was measured from the volume of blood in the suction con-
tainer and from the weight of the soaked gauzes.At the end of liver
resection, the area of the transection surface was measured: the
transection surface was marked on a piece of transparent plastic
sheet and then transcribed to a piece of paper containing marks of
square millimeter for the measurement of the area of the liver
transection surface.
Randomized
Excluded n = 15
Did not meet inclusion criteria 
(poor liver function, not 
resectable liver cancer, 
associated vascular/biliary 
resection): n = 15
Allocated to Kelly group n = 50
Received intervention n = 50
Allocated to LF1212 group n = 50
Received intervention n = 50
Lost to follow-up n = 0 Lost to follow-up n = 0
Analysed n = 50
Excluded from analysis n = 0
Analysed n = 50
Excluded from analysis n = 0
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Figure 1 Study flow chart of a liver resection using Kellyclasia plus humid bipolar coagulation (Kelly group) versus by Ligasuretm Small Jaw
Instrument (Covidien) (LF1212 group)
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In the Kelly group, transection of the liver parenchyma was
performed using a Kelly clamp. Small vessels or bile ducts were
mainly controlled by absorbable clips. In the LF1212 group,
transection of the liver parenchyma was performed using the
Ligasure device; small vessels or bile ducts up to 7 mm were
mainly controlled by the Ligasure vessel sealing system.
The application of topical haemostatic agents to the raw surface
of the liver at the end of the transection was not allowed unless
there was occurrence of persistent bleeding which could not be
controlled otherwise. In this case a topical haemostatic matrix
(Floseal; Baxter Biosurgery, Deerfield, IL, USA) was used.
A bile duct fistula was defined according to the definition of the
International Study Group of Liver Surgery (ISGLS).10 Bilirubin
levels of the drainage liquid were routinely measured on days 3
and 5 after surgery. Liver failure was defined according to the
ISGLS definition11
According to the histological examination of the non-tumoural
liver, the parenchyma was defined as normal in the absence of
any sign of chemotherapy-induced hepatic injury, chronic liver
disease or cirrhosis.12,13
The primary end-point was to the overall and ‘per cm2’ blood
loss during the liver transection.
Secondary outcomes were transection time, transection
speed (calculated as transection area divided by transection time,
cm2/min), width of the resection margin, transfusion rate and bile
leak rate.
Surgical procedure
All operations were performed by two surgeons who were equally
skilled in both liver transection techniques. All resections were
performed under a central venous pressure (CVP) of 5 cmH2O or
less evaluated using a transducer connected to the CVP catheter.
Hepatic pedicle clamping during liver transection was not
performed unless the haemorrhage could not otherwise be
controlled. In this setting, hepatic pedicle clamping was always
intermittent (15 min of clamping and 5 min of release).
Intra-operative ultrasonography was routinely used to guide
the transection line.
A major hepatic resection was defined as a resection of three or
more contiguous segments.
Statistical analysis
According to previous published data, the sample size calculation
was performed with the expectation of a 30–50% difference in
overall and ‘per cm2’ blood loss during a liver resection with a level
of statistical significance of 0.05 and a power of 0.80.4–7 The
accrual target was set at 50 patients for each group.
Results were expressed as median (range). Continuous variables
were compared using the most appropriate non-parametric tests
test; categorical variables were compared using the χ2 of Fisher’s
exact test, as appropriate. The analysis was performed in ‘an
intention-to-treat’ manner. Differences were considered statisti-
cally significant at P < 0.050.
All analyses were performed using statistical software
(StatisticaTM for Windows; StatSoft Italia, Vigonza, Padova, Italy).
Results
Background characteristic
Background characteristics of the two groups are reported in
Table 1. The median number of liver tumours was 2 in the Kelly
group compared with 2.9 in the LF1212 group (P = 0.792). Liver
metastases from colorectal cancer were the most common indica-
tion to hepatic resection: overall, 73% of these patients underwent
neoadjuvant chemotherapy, usually oxaliplatin based.
A major hepatic resection was an uncommon procedure: most
of the patients underwent multiple wedge resections. The liver
transection area was larger in the LF1212 group but the difference
did not reach statistical significance.
Morbidity and mortality
The in-hospital mortality rate was 3% (n = 3). Two patients died
of myocardial ischaemia and liver failure, respectively, 4 and 29
days after a right hepatectomy for colorectal metastases. The last
patient died of sepsis and multiorgan failure 70 days after a left
hepatectomy for hepatocellular carcinoma associated with cirrho-
sis. All the patients who died postoperatively were in the LF1212
group (Table 2).
Thirty-five patients (35%) had post-operative complications.
Overall, 15 patients developed a bile duct fistula: type A in 7
patients, type B in 7 patients and type C in 1 patient. According
to the ISGLS definition, only one patient developed post-
hepatectomy liver failure.11
Study outcome
Statistical analyses revealed no significant differences between the
two groups of the study in terms of overall and ‘per cm2’ blood
loss, transection time, transection speed, transfusion rate, bile leak
rate and resection margin width. In particular, the overall and
‘per cm2’ blood losses were similar in the two groups of the
study whereas there was a tendency towards a higher transection
speed in the LF1212 group: 0.8 cm2/ml versus 1.1 in the Kelly
group (P = 0.089).
At final pathological analysis, the median width of the resection
margin was 6 mm in both groups of the study. The rate of a
positive (0 mm) resection margin was similar in the two groups.
Discussion
Blood loss is one of themost important factors affecting the short-
and long-term outcome of patients undergoing a liver resec-
tion.1,14 Among the ‘technical factors’ influencing intra-operative
blood loss, a liver transection is considered a critical factor. Since
the first report of five hepatic resections performed using the
clamp-crushing technique, this technique has become the gold-
standard form of liver parenchymal transection.7,15 However, in
the past 10–15 years, a number of surgical devices have been
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Table 1 Background characteristics of the 100 patients undergoing a liver resection using Kellyclasia (Kelly group) or the Ligasure Small Jaw
Instrument (LF1212 group)
Factors Kelly group (n = 50) LF1212 group (n = 50) P
Age (years) 64.7 (39.9–84.9) 64.3 (32.5–83.2) 0.893
Pre-operative BMI 26.5 (16.9–35.2) 25.2 (17.1–34.2) 0.123
Number of liver tumours 2 (1–13) 2.9 (1–26) 0.792
Liver tumour
CR Mets (n) 58% (29) 62% (31) 0.683
HCC (n) 22% (11) 34% (17) 0.182
Other (n) 20% (10) 4% (2) 0.014
Neoadj CTx (n) 40% (20) 48% (24) 0.546
Number cycles 6 (3–12) 6 (−2–12) 0.236
Pre-operative serum levels
AST 25 (11–125) 25.5 (11–135) 0.491
ALT 24.5 (8–129) 25 (9–172) 0.937
Bilirubin (mg/dl) 0.6 (0.1–3.6) 0.5 (0.2–2.4) 0.997
PT 100% (49–147) 95 (61–129) 0.343
ALB 4.04 (2.4–4.5) 4.1 (2.9–4.6) 0.941
ICG (%) 6.7 (2.3–14.4) 7.9 () 0.678
Normal liver (n) 50% (25) 36% (18) 0.157
MHR (n) 8% (4) 12% (6) 0.505
Wedge resections 62% (31) 52% (26) 0.209
Multiple resections 46% (23) 42% (21) 0.420
Transection surface area (cm2) 39 (6–200) 51.5 (8–418) 0.116
BMI, body mass index; CR Mets, colo-rectal liver metastases; HCC, hepatocellular carcinoma; Neoadj CTx, neoadjuvant chemotherapy;
AST, aspartate aminotransferase (units/l); ALT, alanine aminotransferase (units/l); PT, prothrombin time (percentage); ALB, albumin (g/dl);
ICG, indocyanine green clearance test; HPC, hepatic pedicle clamping; MHR, major hepatic resection.
Table 2 Study outcome in the two groups of the study
Factors Kelly group (n = 50) LF1212 group (n = 50) P
Overall blood loos (ml) 200 (0–1750) 300 (0–3000) 0.227
Blood loss ‘per cm2’ (ml/cm2) 5.1 (0.64.8) 5.5 (0–27.3-) 0.468
Transection time (min) 60 (5–200) 60 (8–221) 0.944
Transection time ‘per cm2’
(min/cm2) 1.2 (0.2–6.7) 0.9 (0.2–10) 0.089
Transection speed (cm2/ml) 0.8 (02–5.4) 1.1 (0.1–5.5) 0.089
Transfusion rate 26% (n = 13) 32% (n = 16) 0.659
Hepatic pedicle clamping 26% (n = 13) 42% (n = 21) 0.069
Clamping time 26 (7–68) 15 (4–48) 0.033
Mortality 0% (n = 0) 6% (n = 3) 0.121
Morbidity 34% (n = 17) 36% (18) 0.500
Bile leak rate 12% (n = 6) 18% (n = 9) 0.576
Bil drainage day 3 (mg/dl) 1.3 (0.5–50) 1.3 (0.5–24) 0.403
Bil drainage day 5 (mg/dl) 1 (0.3–22.8) 1.4 (0–31.8) 0.093
Resection margin width (mm) 6 (0–30) 6 (0–20) 0.516
Resection margin 0 mm 7 (14%) 8 (16%) 0.500
Hospital stay (days) 7 (4–24) 8 (4–52) 0.789
ml, millilitres; min, minutes; bil, bilirubin; mm, millimetres.
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created for this purpose, i.e. CUSA, bipolar sealing devices and
vascular staplers. Many non-randomized studies have evaluated
various techniques for liver transection claiming superiority of
one method over another.16–18 The few published randomized
studies have failed to show any significant advantage of one of the
new transection methods over the clamp-crushing technique.15
Lesurtel’s trial, which compared four different techniques of liver
transection [(clamp-crushing technique versus CUSA versus
Hydrojet versus dissecting sealer using radiofrequency energy
(Tissuelink, Dover, NH)] showed the superiority of the clamp-
crushing technique.5 However the use of hepatic pedicle clamping
only in the clamp-crushing cohort may have produced a bias. The
LF1212 device is a vessel sealing/divider system which seals vessels
up to 7 mm, lymphatics and tissue bundles. The LF1212 forceps
allow liver parenchymal transection in a similar manner to
the clamp-crushing technique. To our knowledge, the present
randomized study is the first one to evaluate the impact of the
LF1212 device during liver transection. In the present series, the
LF1212 device was demonstrated to be a safe, effective and effi-
cient method for hepatic parenchymal transection even if com-
pared with the ‘gold-standard’ clamp-crushing technique. In 2009,
a randomized study compared the clamp-crushing technique with
a vessel sealing system (Ligasure PreciseTM; Valleylab, Boulder, CO,
USA) similar to the one used in the present study except for the
absence of the cutting knife and the use of an older less efficient
energy platform.19 In both arms of the study, transection of the
liver was performed by Kellyclasia: the only difference was the
sealing of vessels and ducts smaller than 2 mm by the vessel
sealing device in the Ligasure arm whereas vessels and ducts
larger than 2 mm were tied and divided. In the present study, the
transection of the liver parenchyma in the LF1212 group was
performed using the forceps of the vessel sealing device which was
used to seal and divide vessels and ducts up to 7 mm.
A drawback of the use of the LF1212 vessel sealing system is the
higher cost of each device as compared with the clamp-crushing
technique. However, in our practice the use of the LF1212 device
has dramatically reduced the need of costly absorbable clips
during liver transection.
In the present series, the overall bile leakage rate was 15%,
higher than reported in a recent French series but similar to
reported by the Makuuchi group.19,20 Most of the patients under-
went extended and complex wedge resections with a large residual
surface area at the end of the liver transection (median transection
surface area 50 cm2, data not shown). Moreover, half of these
patients had type A fistulae which did not require any further
treatment. Some concerns have been raised regarding the effec-
tiveness of the vessel sealing system in preventing bile leaks after a
liver resection.21 In the present prospective randomized study, the
bile leakage rate was not statistically different between the two
groups of the study. Of note, our sample size was not calculated to
identify a difference in bile leaks. However, adequate sealing of the
intrahepatic bile ducts by the Ligasure vessel sealing system was
recently confirmed at the histolgical analyses of the transected
liver parenchyma.9 Moreover, as the lateral thermal spread of the
Ligasure device is minimal (1 mm) if compared with, i.e. har-
monic scalpel, the LF1212 device can be used close to the hepatic
hilum structures or to the hepatic vein confluence.5
In 2006, a randomized study clearly showed that a liver resec-
tion without hepatic pedicle clamping was safe.2 Since then, we
have performed most of the liver resections without using the
hepatic pedicle clamping. In the present study, unlike the
Lesurtel’s study, hepatic pedicle clamping was not allowed in both
groups of randomization unless the occurrence of a bleed which
could not be controlled otherwise.5 Overall, about one-third of
the patients required hepatic pedicle clamping with a median
clamping time of 23 min. The increased rate of hepatic pedicle
clamping in the LF1212 group may be explained by a less effective
sealing power on the branches of the hepatic veins. In fact, the
vessel sealing technology of the LF1212 works by determining the
fusion of the connective tissue present in the vessel wall. There-
after, as the wall of the hepatic veins is thin with less connective
tissue than the portal or arterial branches and the vessel sealing
may be less effective thus increasing the risk of back-flow bleed-
ing, hepatic pedicle clamping may be used more frequently when
working close to the hepatic vein confluence. However, the
median clamping time in the LF1212 group was short (15 min).
Clamping times shorter than 40 min are associated with minimal
cellular injury.22
The frequent use of neoadjuvant chemotherapy and the ten-
dency to resect multiple, bilateral liver metastases have increased
both the risk and the ‘need’ to have narrow resection margins.
However, although a positive resection margin increases the risk
of margin recurrence, the tumour biology and not the width of
the resection margin affects the long-term outcome.23,24 In the
present series, only 15% of the patients had a positive resection
margin, in spite of the mean number of resected colorectal liver
metastases being high (n = 4, data not shown). The technique of
liver resection did not impact on the width of the resection
margins. The results of the present study compares favourably
with those shown by a French study reporting a 24% rate of
positive resection margins.25
The accrual target set at 50 patients for each group was large
enough to detect a 30–50% difference in blood loss during liver
transection. However, as very few studies have been published
that evaluate the vessel-sealing system technique during liver
transection, it might be that the reported difference was too high
and, thereafter, the ‘50 patients per-group’ target too low to detect
significant differences in terms of blood loss.
In conclusion, a liver resection with the LigasureTM Small Jaw
Instrument is associated with similar results in terms of blood
loss, transection speed and bile leak rate compared with the con-
ventional clamp-crushing technique. However, the Kelly shape of
the Ligasure device which allows accurate and safe liver crushing
similar to the ‘classic’ clamp-crushing technique may increase the
surgeon’s ‘comfort’ which is difficult to measure but critically
important for the completion of a liver resection.
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